tirzepatide eu approval UK first country in Europe to reimburse Tirzepatide | Research Peptide |

DHA protects against monosodium urate-induced inflammation through modulation of oxidative stress

The SURMOUNT-1 trial (N=2,539), published in the New England Journal of Medicine in 2022 (DOI: 10.1056/NEJMoa2206038), evaluated tirzepatide at 5mg, 10mg, and 15mg weekly doses versus placebo in adults with obesity or overweight

NICE-recommended IBS treatments include dietary modification, antispasmodics, laxatives or antimotility agents, and psychological therapies

Metabolic adaptation during GLP-1 therapy is less severe than with traditional dieting, which is one of the major advantages of GLP-1 medications

People who stopped Semaglutide regained 50-63% of their prior weight loss within a year

Supplementation may be appropriate, especially in regions with limited sun exposure